Movetis Introduces Resolor In UK

Resolor (prucalopride) is a new enterokinetic agent that represents a new approach to the symptomatic treatment of chronic constipation (in women in whom laxatives fail to provide adequate relief) as it targets underlying impaired gut motility.

Movetis said that the clinical benefits and the favourable safety profile of Resolor in chronic constipation have been demonstrated in a clinical development programme with over 3,000 patients treated for the equivalent of more than 2,600 patient years1.

Dirk Reyn, CEO of Movetis, said: “Reactions from key gastroenterologists to Resolor in Germany are very encouraging. With today’s market introduction in the UK, Movetis is now present in two of the five European markets where we intend to build our own commercial organisations.

“As in Germany, we have been able to attract a high-quality core team in the UK with significant experience in launching pharmaceutical products. I am confident that this team too can optimise the full commercial potential of Resolor and further develop our local UK organisation.”

Later in 2010, Movetis expects to launch Resolor in the Netherlands and to continue the preparations for the product launch in France and Belgium (including Luxemburg) in 2011.

In addition, Movetis is continuing to pursue its strategy of seeking commercial partnerships to roll-out Resolor in the European Economic Area beyond these five markets. Movetis is also continuing to work with Johnson & Johnson to prepare for the filing and eventual launch of Resolor outside Europe.

Movetis has set up a collaboration with the UK-based company IDIS in order to provide pre-launch access to Resolor in those countries where the product has received marketing approval but where the pricing and reimbursement procedures are still ongoing, and where this is allowed by national regulations.